Cargando…

SA8 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in COPD in England: A Population-Based Study

Detalles Bibliográficos
Autores principales:	Ismaila, AS, Tritton, T, Han, X, Holbrook, T, Numbere, B, Ford, AF, Massey, L, Fu, Q, Hutchinson, FM, Birch, HJ, Leather, D, Sharma, R, Compton, C, Rothnie, KJ
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747452/ http://dx.doi.org/10.1016/j.jval.2022.09.2402

Ejemplares similares

SA62 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in Asthma in England: A Population-Based Study
por: Rothnie, KJ, et al.
Publicado: (2022)

Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
por: Rothnie, Kieran J, et al.
Publicado: (2022)

Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK
por: Rothnie, Kieran J, et al.
Publicado: (2023)

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
por: Ismaila, Afisi S., et al.
Publicado: (2023)

Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England
por: Sansbury, Leah B, et al.
Publicado: (2022)

Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
por: Requena, Gema, et al.
Publicado: (2023)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
por: Requena, Gema, et al.
Publicado: (2023)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2023)

EE468 Healthcare Resource Utilisation and Costs Associated With the Management of Hospitalised COVID-19 Patients in England
por: Patel, V, et al.
Publicado: (2022)

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
por: Requena, Gema, et al.
Publicado: (2023)

Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2022)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
por: Requena, Gema, et al.
Publicado: (2022)

Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting
por: Halpin, David M G, et al.
Publicado: (2022)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD
por: Ronco, Raffaella, et al.
Publicado: (2023)

Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review
por: Czira, Alexandrosz, et al.
Publicado: (2023)

Estimating the cost and epidemiology of mild to severe chronic pain associated with osteoarthritis in England: a retrospective analysis of linked primary and secondary care data
por: Lohan, Christoph, et al.
Publicado: (2023)

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis
por: Brookes, Matthew J, et al.
Publicado: (2020)

Variations in Demand across England for the Magnetic Resonance-Linac Technology, Simulated Utilising Local-level Demographic and Cancer Data in the Malthus Project
por: Mee, T., et al.
Publicado: (2021)

The impact of COVID-19 on mental health service utilisation in England
por: Villaseñor, Adrián, et al.
Publicado: (2023)

COPD exacerbations by disease severity in England
por: Merinopoulou, Evie, et al.
Publicado: (2016)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis
por: Fabiano, G., et al.
Publicado: (2022)

Healthcare resource utilisation and cost of pneumococcal disease from 2003 to 2019 in children ≤17 years in England
por: Mohanty, Salini, et al.
Publicado: (2023)

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
por: Kendall, Robyn, et al.
Publicado: (2023)

Health Resource Utilisation and Disparities: an Ecological Study of Admission Patterns Across Ethnicity in England Between 2017 and 2020
por: Toal, C. M., et al.
Publicado: (2022)

Drug utilisation in neonatal units in England and Wales: a national cohort study
por: Al-Turkait, Asma, et al.
Publicado: (2022)

Utilising the dental workforce in England, United Kingdom, to optimise the response to COVID-19
por: Wilson, Gavin J, et al.
Publicado: (2023)

1743. Health Care Resource Utilisation (HCRU) Due to Respiratory Syncytial Virus (RSV) Before the Age of Two in England
por: Fonseca, Maria João, et al.
Publicado: (2023)

Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care
por: Rothnie, Kieran J, et al.
Publicado: (2017)

Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France
por: Whittaker, Hannah, et al.
Publicado: (2022)

Critical care utilisation following bariatric surgery
por: Whiting, P, et al.
Publicado: (2007)

SA5 The Effectiveness and Safety of Remdesivir for COVID-19: A Quantitative Meta-Analysis
por: Mohamed, AF, et al.
Publicado: (2022)

Projecting the COPD population and costs in England and Scotland: 2011 to 2030
por: McLean, Susannah, et al.
Publicado: (2016)

COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners
por: Meeraus, Wilhelmine, et al.
Publicado: (2018)

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
por: Halpin, David M.G., et al.
Publicado: (2021)

Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis
por: Rothnie, Kieran J, et al.
Publicado: (2015)

Comparison of COPD primary care in England, Scotland, Wales, and Northern Ireland
por: Stone, Philip W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_srq057n7bkun7hmbk5m3lv2ha2